

Journal of Visualized Experiments

Polyethyleneimine-coated iron oxide nanoparticles as a vehicle for delivery of small interfering RNA to macrophages in vitro and in vivo

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58660R2
Full Title:	Polyethyleneimine-coated iron oxide nanoparticles as a vehicle for delivery of small interfering RNA to macrophages in vitro and in vivo
Keywords:	macrophage; transfection; nanoparticle; siRNA delivery; polyethylenimine; vehicle; gene silencing
Corresponding Author:	Xiaohua Mao Southeast University Nanjing, CHINA
Corresponding Author's Institution:	Southeast University
Corresponding Author E-Mail:	xmao@seu.edu.cn
Order of Authors:	Na Jia Haoan Wu Juanli Duan Chunxue Wei Yu Zhang Xiaohua Mao
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Nanjing, Jiangsu, China

Dear Dr. Steindel,

Thank you for your time in editing our ms. Listed below are answers to your concerns and we have accordingly revised our ms. The changes in the revision are shown in red.

Sincerely,

Xiaohua Mao

1. Figure 1: Where do the siRNA-PEI-SPION complexes go in the gel, then? Also, what do you mean by a ‘value of 0’ -the Fe-siRNA ratio?

Authors’ response: The siRNA band can be either retarded or not detectable upon binding to PEI-SPIONs (stated in protocol 2.6). The latter case reflects a strong binding ability of PEI-SPIONs with siRNA, which results in an exclusion of EB to siRNA during staining. The explanation is now given in the legend to figure 1. Value of 0 has been defined in the legend.

2. Figure 2: What is M2 and PE-H?

Authors’ response: They have been defined in the legend to figure 2.

3. Figure 3: What are the percentages here?

Authors’ response: Now defined in the legend to figure 3.

TITLE:

Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages *In Vitro* and *In Vivo*

AUTHORS AND AFFILIATIONS:

Na Jia¹ *, Haoan Wu² *, Juanli Duan¹, Chunxue Wei¹, Yu Zhang², Xiaohua Mao³

¹Key Laboratory of Ministry of Education for Developmental Genes & Human Diseases, Institute of Life Sciences, Southeast University, Nanjing, China

²State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials & Devices, School of Biological Science & Medical Engineering, Southeast University, Nanjing, China

³Key Laboratory of Ministry of Education for Developmental Genes & Human Diseases, Medical School, Southeast University, Nanjing, China

* These authors contributed equally.

Corresponding Authors:

Xiaohua Mao (xmao@seu.edu.cn)

Tel: (25)-8327-2474

Yu Zhang (Zhangyu@seu.edu.cn)

Tel: (25)-8327-2476

E-mail Addresses of the Co-authors:

Na Jia (220162943@seu.edu.cn)

Haoan Wu (230159675@seu.edu.cn)

Juanli Duan (220102666@seu.edu.cn)

Chunxue Wei (220173409@seu.edu.cn)

KEYWORDS:

Macrophage, transfection, nanoparticle, siRNA delivery, polyethyleneimine, vehicle, gene silencing

SUMMARY:

We describe a method of using polyethyleneimine (PEI)-coated superparamagnetic iron oxide nanoparticles for transfecting macrophages with siRNA. These nanoparticles can efficiently deliver siRNA to macrophages *in vitro* and *in vivo* and silence target gene expression.

ABSTRACT:

Because of their critical role in regulating immune responses, macrophages have continuously been the subject of intensive research and represent a promising therapeutic target in many disorders, such as autoimmune diseases, atherosclerosis, and cancer. RNAi-mediated gene silencing is a valuable approach of choice to probe and manipulate macrophage function;

however, the transfection of macrophages with siRNA is often considered to be technically challenging, and, at present, few methodologies dedicated to the siRNA transfer to macrophages are available. Here, we present a protocol of using polyethyleneimine-coated superparamagnetic iron oxide nanoparticles (PEI-SPIONs) as a vehicle for the targeted delivery of siRNA to macrophages. PEI-SPIONs are capable of binding and completely condensing siRNA when the Fe:siRNA weight ratio reaches 4 and above. *In vitro*, these nanoparticles can efficiently deliver siRNA into primary macrophages, as well as into the macrophage-like RAW 264.7 cell line, without compromising cell viability at the optimal dose for transfection, and, ultimately, they induce siRNA-mediated target gene silencing. Apart from being used for *in vitro* siRNA transfection, PEI-SPIONs are also a promising tool for delivering siRNA to macrophages *in vivo*. In view of its combined features of magnetic property and gene-silencing ability, systemically administered PEI-SPION/siRNA particles are expected not only to modulate macrophage function but also to enable macrophages to be imaged and tracked. In essence, PEI-SPIONs represent a simple, safe, and effective nonviral platform for siRNA delivery to macrophages both *in vitro* and *in vivo*.

INTRODUCTION:

Macrophages are a type of innate immune cells distributed in all body tissues, albeit in different amounts. By producing a variety of cytokines and other mediators, they play critical roles in the host defense against invading microbial pathogens, in tissue repair following injury, and in maintaining tissue homeostasis¹. Due to their importance, macrophages have continuously been the subject of intensive research. However, despite its prevalence in gene regulation and function studies, siRNA-mediated gene silencing is less likely to succeed in macrophages because these cells—particularly, primary macrophages—are often difficult to transfect. This can be ascribed to a relatively high degree of toxicity associated with most well-established transfection approaches in which the cell membrane is chemically (*e.g.*, with polymers and lipids) or physically (*e.g.*, by electroporation and gene guns) disrupted to let siRNA molecules cross the membrane, thereby drastically reducing macrophages' viability^{2,3}. Furthermore, macrophages are dedicated phagocytes rich in degradative enzymes. These enzymes can damage the integrity of siRNA, weakening its silencing efficiency even if gene-specific siRNA has been delivered into the cell^{3,4}. Therefore, an effective macrophage-targeted siRNA delivery system needs to protect the integrity and stability of siRNA during delivery⁴.

It is increasingly evident that dysfunctional macrophages are implicated in the initiation and progression of certain common clinical disorders like autoimmune diseases, atherosclerosis, and cancer. For this reason, modulating macrophage function with, for instance, siRNA, has been emerging as an attractive methodology for treating these disorders⁵⁻⁷. Although much progress has been made, a major challenge of siRNA-based treatment strategy is the poor cell specificity of systemically administered siRNA and the insufficient siRNA uptake by macrophages, which consequently lead to undesired side effects. Compared with free nucleic acid therapeutics that usually lack optimal cell selectivity and often lead to off-target adverse effects, drug-loaded

nanoparticles (NPs), owing to their spontaneous propensity of being captured by the reticuloendothelial system, can be engineered for passive targeting to macrophages *in vivo*, allowing for improved therapeutic efficacy with minimal side effects⁸. Current NPs explored for the delivery of RNA molecules include inorganic nanocarriers, various liposomes, and polymers⁹. Among them, polyethyleneimine (PEI), a type of cationic polymers capable of binding and condensing nucleic acids into stabilized NPs, shows the highest RNA delivering capacity^{9,10}. PEI protects nucleic acids from enzymatic and nonenzymatic degradation, mediates their transfer across the cell membrane, and promotes their intracellular release. Although initially introduced as a DNA delivery reagent, PEI was subsequently demonstrated to be an attractive platform for *in vivo* siRNA delivery, either locally or systemically^{9,10}.

Superparamagnetic iron oxide nanoparticles (SPIONs) have shown great promise in biomedicine, owing to their magnetic properties, biocompatibility, comparable size to biologically important objects, high surface-area-to-volume ratio, and easily adaptable surface for bioagent attachment¹¹. For instance, because of their potential utility as a contrast agent and rapid uptake by macrophages, SPIONs have emerged as a favorite clinical tool to image tissue macrophages¹². While SPIONs have also been extensively studied as nucleic acid delivery vehicles^{11,13-15}, to our knowledge, the literature contains few reports of SPIONs as a carrier for macrophage-targeted siRNA delivery. For gene delivery by SPIONs, their surface is usually coated with a layer of hydrophilic cationic polymers onto which negatively charged nucleic acids can be electrostatically attracted and tethered. Here, we present a method for synthesizing SPIONs whose surface is modified with low-molecular-weight (10 kDa), branched PEI (PEI-SPIONs). These magnetic nanoplatfroms are then employed to condense siRNA, forming PEI-SPION/siRNA complexes that enable siRNA transport into the cell. We reason that spontaneous phagocytosis of SPIONs by cells of the reticuloendothelial system¹⁶, coupled with the strong ability of binding and condensing nucleic acids by PEI, renders PEI-SPIONs suitable for the efficient transport of siRNA into macrophages. The data presented here support the feasibility of PEI-SPION/siRNA-mediated gene silencing in macrophages in culture as well as *in vivo*.

PROTOCOL:

All methods involving live animals were performed in accordance with the animal care and use guidelines of Southeast University, China.

1. Preparation of PEI-SPIONs

1.1. Preparation of oleic acid-modified SPIONs

1.1.1. Dissolve $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ and $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ in water under the protection of N_2 .

1.1.1.1. Add 28 g of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ and 20 g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ into 80 mL of deionized water in a beaker. Introduce N_2 into the water through a glass conduit and stir until the solid matter has dissolved.

1.1.1.2. Heat the reaction mixture to 72 °C at a stirring rate of 800 rpm, followed by addition of 40 mL of ammonia water (28%). Stir for 5 min.

1.1.2. Add 9 mL of oleic acid dropwise into the above-mentioned solution and stir it at 72 °C for 3 h.

1.1.3. Cool the resulting solution to room temperature (RT). Precipitate the solution *via* magnetic separation.

1.1.4. Wash the precipitate containing SPIONs 3x with absolute ethyl alcohol and, then, disperse the precipitate in 100 mL of N-hexane.

1.2. Preparation of dimercaptosuccinic acid-modified SPIONs

1.2.1. Add 800 mg of oleic acid (OA)-modified SPIONs dispersed in 200 mL of N-hexane, and 400 mg of dimercaptosuccinic acid (DMSA) dispersed in 200 mL of acetone, into a three-neck flask in a water bath at 60 °C.

Note: To determine the mass of OA-modified SPIONs, volatilize the N-hexane and weigh the powder.

1.2.2. Add 200 µL of triethylamine dropwise into the above-mentioned solution with stirring at 1,000 rpm and refluxing.

1.2.3. After 5 h of stirring and refluxing, obtain a black precipitate by magnetic separation.

1.2.4. Disperse the hydrophilic SPIONs in deionized water homogeneously by adjusting the pH of the solution using tetramethylammonium hydroxide.

1.3. Preparation of PEI-SPIONs

1.3.1. Add DMSA-modified SPION colloidal solution dropwise into PEI solution (10 kDa) in a 500-mL three-neck flask under mechanical stirring at 1,000 rpm for 2 h ($W_{Fe}:W_{PEI} = 1:3$).

Note: The charge and size of PEI-SPIONs vary depending on the ratio of W_{Fe} to W_{PEI} . The $W_{Fe}:W_{PEI}$ ratio of 1:3 can be a good starting point for synthesizing PEI-SPIONs suitable for siRNA delivery.

1.3.2. Add the resultant solution into an ultrafiltration tube having a molecular weight cutoff of 100 kDa and a content of 15 mL; then, centrifuge at 5,400 x g for 10 min until the remaining solution is 1 mL. Add deionized water to the solution to make the volume 15 mL again and repeat

the above process 10x to obtain the final product. Then, filter the solution through a 0.22- μ m filter and store the final product at 4 °C.

1.3.3. Determine the Fe concentration of PEI-SPIONs by the colorimetric method using phenanthroline¹⁷. Dilute PEI-SPIONs with deionized sterile water to a concentration of 1 mg Fe/mL and store it at 4 °C.

1.3.4. Dilute 10 μ L of the PEI-SPION solution (1 mg Fe/mL) to 1 mL with deionized water; then, test its hydrodynamic size and zeta potential by a dynamic light-scattering device.

Note: Prepare PEI-SPIONs in the range of about 30 - 50 nm. In this size range, the effect of the NP size on siRNA binding and cellular uptake does not appear to be significant. PEI-SPIONs bearing an average zeta potential over +37 mV can be toxic in the dose range for transfection, and a cytotoxicity assay should be performed to ensure safety. The surface charge and hydrodynamic size of the nanoparticles can be controlled within a desired range by adjusting the PEI content.

2. Preparation and Agarose Gel Electrophoresis of PEI-SPION/siRNA NPs

2.1. Dilute siRNA with RNase-free water to yield a final concentration of 20 μ M (0.26 μ g/ μ L).

2.2. Prepare five RNase-free microcentrifuge tubes labeled 0, 1, 2, 4, and 8. The labels represent different Fe:siRNA weight ratios. Pipet 3 μ L of siRNA solution to all tubes (\sim 0.8 μ g of siRNA/tube).

2.3. Add 0, 0.8, 1.6, 3.2, and 6.4 μ g of Fe in the form of PEI-SPIONs to the tubes labeled 0, 1, 2, 4, and 8, respectively. Keep the total sample volume of each tube less than 20 μ L. Mix by gently pipetting up and down.

2.4. Incubate the mixtures at RT for 30 min to allow PEI-SPION/siRNA complex formation. During this period, make a 3% agarose gel with high-purity agarose.

Note: Additional PEI-SPION/siRNA complexes with other Fe:siRNA ratios (*e.g.*, 5 or 6) can be prepared and tested.

2.5. Add 1 μ L of 6x DNA-loading buffer per 5- μ L sample and mix cautiously. Load all samples and run electrophoresis at 5 V/cm until the bromophenol blue migrates as far as two-thirds of the length of the gel. Stain the gel with ethidium bromide (EB) for 15 - 20 min.

Note: Freshly prepared electrophoresis buffer and EB solution should be used.

2.6. Visualize siRNA bands under a UV imaging system. Check the Fe:siRNA ratios at which siRNA

forms complexes with PEI-SPIONs and, as a result, the bands representing free siRNA are retarded or not detectable.

3. Transfection of RAW264.7 Macrophages *In Vitro*

3.1. Culture mouse macrophage-like RAW264.7 cells in a 10-cm dish using DMEM complete medium containing 10% fetal bovine serum (FBS) per 100 U/mL penicillin per 100 µg/mL streptomycin at 37 °C in a 5% CO₂ incubator.

3.2. One day prior to the transfection, aspirate medium from the cells and rinse them with phosphate-buffered saline (pH 7.4). Add 1 mL of 0.25% trypsin to the 10-cm dish. Trypsinize RAW264.7 cells for about 5 - 10 min at 37 °C in a 5% CO₂ incubator.

3.3. When the majority of the cells have detached (after 5 - 10 min), add 5 mL of DMEM complete medium to the dish to inactivate the trypsin. Pipet up and down to disperse cell clusters into single cells.

3.4. Transfer the cell suspension to a sterile 15-mL conical tube. Centrifuge it at 300 x g for 3 min at RT. Remove the supernatant.

3.5. Resuspend the cells with 5 mL of fresh DMEM complete medium and count the cells.

3.6. Plate 9×10^4 cells per well in a 6-well plate with 2 mL of complete DMEM medium and incubate at 37 °C in a 5% CO₂ incubator for about 24 h.

Note: If using a plate of a different size, adjust the plated cell density in proportion to the relative surface area so that the cells reach 80% confluency at the time of transfection.

3.7. When cell confluency is 80%, remove the medium from the cells and replace it with 1 mL of DMEM complete medium per well. Return the plate to the incubator until PEI-SPION/siRNA complexes have been prepared and are ready for use (about 30 min).

3.8. Prepare PEI-SPION/siRNA complexes: calculate the amount of PEI-SPION/siRNA complexes needed for a transfection experiment. In a 1.5-mL RNase-free microcentrifuge tube, mix an appropriate amount of PEI-SPIONs with siRNA at a given Fe:siRNA ratio. For instance, to prepare PEI-SPION/siRNA NPs containing 100 µg of Fe at a Fe:siRNA ratio of 4, add 100 µL (1 mg Fe/mL) of PEI-SPIONs to 96 µL of siRNA (0.26 µg/µL), followed by mixing it gently with a micropipette. Incubate for 30 min at RT.

Note: Prepare a volume of PEI-SPION/siRNA complex that is 10% in excess of the total final mass to account for any incidental losses. Make PEI-SPION/siRNA complexes at low Fe:siRNA ratios,

under which siRNA molecules are completely loaded onto PEI-SPIONs and, hence, small amounts of PEI-SPIONs can be used to minimize potential cytotoxicity. Pilot experiments (gel retardation assay) for the optimization of the Fe:siRNA ratio are necessary.

3.9. Take out the 6-well plate from the incubator (step 3.7). Add a required volume of PEI-SPION/siRNA complex dropwise to each well and swirl the plate cautiously to ensure an even distribution. Return the plate to the incubator until the assessment of the cellular uptake or gene knockdown efficiency (1 - 3 d).

Note: Transfecting macrophages with PEI-SPION/siRNA at a concentration of ~15 µg Fe/mL may maximize transfection efficiency while minimizing potential cytotoxicity.

4. Systemic Delivery of siRNA to Macrophages in Rats with Experimental Arthritis

4.1. Obtain specific pathogen-free male Wistar rats that are 7 weeks old. Habituate the rats for 7 d prior to use and provide them with adequate food and water. Induce adjuvant arthritis (AA) in the rats as previously described¹⁸.

4.2. Prepare PEI-SPION/siRNA complexes as described in step 3.8.

4.3. Inject the PEI-SPION/siRNA NPs (0.3 mg of siRNA/kg) into the AA rats *via* the tail vein. Assess the cellular uptake *via*, for instance, flow cytometry, tissue biodistribution *via*, for instance, a real-time fluorescence imaging system, or therapeutic effects based on, for instance, clinical, histologic, and radiographic analyses at desired time points¹⁸.

Note: For cellular and tissue biodistribution studies, treat the rats with a single injection of the desired NPs; for therapeutic studies, inject the rats with the NPs to be tested 1x a week for three consecutive weeks.

REPRESENTATIVE RESULTS:

The size and zeta potential of PEI-SPIONs prepared with this protocol were in the range of 29 - 48 nm (polydispersity index: 0.12 - 0.23) and 30 - 48 mV, respectively. They were stable in water at 4 °C for over 12 months without obvious aggregation. To evaluate their siRNA binding ability, PEI-SPIONs were mixed with siRNA at various Fe:siRNA weight ratios. **Figure 1** shows that when the Fe:siRNA weight ratio reaches 4 and above, the band of free siRNA was completely missing, implying successful siRNA binding to PEI-SPIONs. A major concern of PEI in biomedical application is its toxicity, which is a result of the strong positive charge, particularly at high molecular weights and high doses. As shown in **Figure 2A**, PEI-SPIONs with a zeta potential of 30.5 and 37 mV did not exhibit apparent cytotoxicity at concentrations up to 30 µg Fe/mL, which is about twofold higher than the concentration (15 µg Fe/mL) normally used for cell transfection. However, PEI-SPIONs with a zeta potential of 48 mV were toxic even at the lowest dose examined (10 µg Fe/mL).

Therefore, PEI-SPIONs possess a charge-dependent toxicity. Since cationic charge is not important for the NP uptake by macrophages¹⁹, we suggest that PEI-SPIONs with an average zeta potential not higher than +37 mV are used for the siRNA transfer, although siRNA binding would decrease the charge to some extent and alleviate cytotoxicity¹⁸.

To test the potential application of PEI-SPIONs for siRNA delivery to macrophages, the *in vitro* transfection was performed with the murine macrophage cell line RAW 264.7. As analyzed by flow cytometry, more than 90% of the cells were transfected with fluorescently labeled PEI-SPION/siRNA complexes at 15 $\mu\text{g Fe/mL}$ (**Figure 2B**). With respect to transfection efficiency, there was actually no difference between PEI-SPION/siRNA NPs formed at Fe:siRNA weight ratios of 4 and 8, although, under the latter condition, the NPs that were formed were smaller in size and weaker in positive charge because a lesser amount of siRNA was loaded per particle. We also assessed the effect of PEI-SPION/siRNA concentration on cellular internalization by Prussian blue staining. As shown in **Figure 2C**, the blue spots within the transfected cells were minimally detectable at 7.5 $\mu\text{g Fe/mL}$, but clearly visible at 15 $\mu\text{g Fe/mL}$. Interestingly, increasing the PEI-SPION/siRNA concentration to 32 $\mu\text{g Fe/mL}$ did not increase the staining intensities, probably because the PEI-SPION/siRNA uptake was saturated at concentrations around 15 $\mu\text{g Fe/mL}$. In addition, the ability of PEI-SPIONs for mediating the siRNA transfer was corroborated in primary macrophages¹⁸, and the method presented here had a high siRNA transfection efficiency in rat peritoneal macrophages, equivalent to that in RAW264.7 cells. The peritoneal macrophages transfected with PEI-SPIONs harboring specific siRNA showed a significant decrease in the target mRNA level as compared with nonspecific siRNA (**Figure 2D**), implying that siRNA could escape from endocytosis vesicles into the cytoplasm and reach the RNAi machinery.

We previously also investigated the *in vivo* cellular uptake of systemically administered PEI-SPION/siRNA complexes in rats with adjuvant arthritis¹⁸. We analyzed PEI-SPION/siRNA transfection efficiency in phagocytic macrophages and nonphagocytic T lymphocytes. As shown in **Figure 3**, CD11b+ cells took up PEI-SPION/siRNA complexes more efficiently than CD3+ cells at any time point in all of the organs examined, indicating that PEI-SPION/siRNA NPs preferentially target macrophages¹⁸. Notably, a high-level accumulation of the NPs was observed in inflamed joints¹⁸, suggesting that the PEI-SPION can be an attractive platform for the systemic delivery of siRNA therapeutics in rheumatoid arthritis whose pathogenesis is linked to macrophage dysfunction and for which local siRNA administration is not a favorite choice due to the involvement of multiple organs of the disease.

FIGURE LEGENDS:

Figure 1: Agarose gel electrophoresis of PEI-SPION/siRNA complexes formed at various Fe:siRNA (w/w) ratios. A Fe:siRNA ratio of 0 represents free siRNA duplexes without PEI-SPIONs. The average size and zeta potential of the free PEI-SPIONs used here were 30 nm and 45 mV. siRNA could completely bind to PEI-SPIONs when the Fe:siRNA ratio reaches 4 and above, consistent

with the previous results using PEI-SPIONs with an average size of 48 nm and a zeta potential of 30.5 mV¹⁸. The absence of retarded bands (PEI-SPION/siRNA complexes) may reflect inaccessibility of siRNA to EB during staining, an indication of strong siRNA binding, and/or the condensing ability of PEI-SPIONs.

Figure 2: Biological characterization of PEI-SPION and PEI-SPION/siRNA NPs. (A) This panel shows a cell viability assay. RAW 264.7 cells were treated for 16 h with the indicated doses of PEI-SPIONs bearing different zeta potential and, then, an MTS assay was performed. The cell viability was normalized against the control (no particle exposure). The data are the mean \pm SD of duplicate wells. (B) This panel shows a flow cytometric analysis of the PEI-SPION/Cy3-siRNA uptake by RAW 264.7 cells. The cells were incubated for 24 h with 15 μ g Fe/mL (upper panel) or 5 μ g Fe/mL (lower panel) of PEI-SPIONs complexed with Cy3-labeled siRNA at a Fe:siRNA (w/w) ratio of 4 and 8, respectively. Nonspecific (NC) siRNA represents non-fluorescent siRNA. M2: gated region; Pe-H: Cy3 fluorescence intensity. The siRNA transfection efficiency of PEI-SPIONs used here (37.8 nm, 48 mV) was similar to a previous study using PEI-SPIONs with an average size of 48 nm and a zeta potential of 30.5 mV¹⁸. (C) This panel shows an analysis of PEI-SPION/siRNA uptake by visualizing cellular iron deposits. RAW 264.7 cells were incubated with 7.5, 15, and 32 μ g Fe/mL PEI-SPIONs (48 nm, 30.5 mV) complexed with siRNA (Fe:siRNA = 8) and stained by Prussian blue. The scale bars are 20 μ m. (D) This panel shows an *in vitro* validation of the silencing efficiency of siRNA delivered by PEI-SPIONs. A specific siRNA-targeting rat IL-2/-15 receptor β chain was loaded onto PEI-SPIONs (48 nm, 30.5 mV) at Fe:siRNA = 8 and, then, transfected into rat peritoneal macrophages. An NC siRNA was used as control. The gene silencing effect was assessed by quantitative PCR. The cells were incubated with the complexes at 15 μ g Fe/mL. The data are the mean \pm the SD of triplicate wells. Panel D has been modified from Duan *et al.*¹⁸ with permission from the publisher.

Figure 3: *In vivo* cellular uptake of PEI-SPION/siRNA NPs. Three arthritic rats were injected intravenously with a single dose of 0.3 mg/kg Cy3-siRNA formulated with PEI-SPION (48 nm, 30.5 mV). A rat injected with PBS was used as a control. Blood, spleen, liver, kidney, and inflamed joints were collected at 2, 8, and 24 h after the injection. The cellular uptake of PEI-SPION/Cy3-siRNA NPs was assessed by flow cytometry using (A) anti-CD3 and (B) anti-CD11b monoclonal antibodies. The percentages are of Cy3-siRNA uptake within the gated CD3+ or CD11b+ cells. The results shown here are representative of two independent experiments. This figure has been modified from Duan *et al.*¹⁸ with permission from the publisher.

DISCUSSION:

Macrophages are refractory to transfect by commonly used nonviral approaches, such as electroporation, cationic liposomes, and lipid species. Here we described a reliable and efficient method to transfect macrophages with siRNA. Using the present protocol, over 90% of macrophage-like RAW 264.7 cells (Figure 2B) and rat peritoneal macrophages¹⁸ can be transfected with siRNA without significant impairment of the cell viability. This method depends

on the delivery platform PEI-SPION, which is a nanocarrier composed of a core of iron oxide and a shell of PEI. So, the first key step of the protocol is the synthesis of PEI-SPIONs suitable for siRNA delivery. Usually, PEI-coated SPIONs are prepared from oleic acid-coated SPIONs by a ligand-exchange method in which oleic acid is directly exchanged from the surface of SPIONs by PEI or its derivatives¹⁵, generating hydrophilic NPs with a positively charged surface. In the case presented here, the oleic acid capped on the surface of SPIONs was replaced by water-soluble dimercaptosuccinic acid, and then PEI was loaded onto SPION surfaces through electrostatic interactions. This method is gentle and easy to prepare in large quantities, and the synthesized NPs have excellent stability in water²⁰. It is well-known that PEI is cytotoxic, and the toxicity correlates strongly with its molecular weight²¹. To ensure safety, an important consideration when synthesizing PEI-SPIONs is that these particles are coated with low-molecular-weight PEI, which is 10 kDa in this protocol. The undesired toxic effect of PEI is mainly mediated by its positive charge; therefore, the measurement of the zeta potential of PEI-SPIONs is essential, and the value should be not higher than 37 mV. A decrease in positive charge can be achieved simply by reducing the PEI content. Another critical step for the successful application of this siRNA delivery system is the optimization of the Fe:siRNA ratio by gel retardation. It seems reasonable to make PEI-SPION/siRNA complexes at low Fe:siRNA ratios under which siRNA molecules are still capable of binding to PEI-SPIONs. In this circumstance, small amounts of PEI-SPIONs can be used, thus minimizing its potential cytotoxicity.

In case a desired silencing efficiency or therapeutic effect is not produced, check the transfection efficiency by flow cytometry or fluorescence microscopy using the carrier loaded with a fluorescently labeled siRNA. Alternatively, the PEI-SPION/siRNA uptake can be examined by conventional Prussian blue staining, which is sensitive enough to detect single granules of iron in cells. If the transfection efficiency is indeed low, it may be required to optimize transfection conditions such as cell density, transfection time, and the dose of PEI-SPION/siRNA particles. The cell passage number can also affect the efficiency of transfection²². In most cases, an insufficient silencing effect is not caused by an insufficient PEI-SPION/siRNA uptake, as the present PEI-SPION system has been demonstrated to facilitate an effective siRNA transfer to macrophages. Sometimes, combining several siRNAs targeting the same gene can be a good strategy to enhance knockdown efficiency. It is noteworthy that, although RNAi generally occurs within 24 h of transfection, the onset and duration of gene silencing depend on the turnover rate of the target, the rate of dilution and longevity of siRNA, and even the concentration of serum in the medium. Thus, time course experiments may be needed to accurately determine the time point of maximal effect^{2,22}. For *in vivo* application, the therapeutic efficacy also depends on whether, and to what extent, the siRNA target contributes to disease phenotypes; thus, the choice of an appropriate siRNA target is critical for expected results.

There are several advantages of this protocol for delivering siRNA to macrophages. (1) The method is easy to perform and is a cheap way to produce PEI-SPIONs in large quantities, and the NPs produced are stable in water for over 12 months if they are kept at 4 °C. (2) Spontaneous

phagocytosis of SPIONs by macrophages facilitates an effective PEI-SPION-mediated siRNA transfer, resulting in high transfection efficiency. It is expected that besides RAW 264.7 cells and rat peritoneal macrophages, this approach is applicable to other macrophage cell lines and primary macrophages, as long as the dose for transfection is optimized. (3) siRNA transfection is fast and easy to conduct compared with other macrophage transfection methods such as nucleofection, which is time-consuming and requires a Nucleofector device². (4) PEI-SPION can be an ideal vehicle for macrophage-targeted systemic siRNA delivery in certain disease models. Macrophages play critical roles in the development and progression of various chronic inflammatory disorders, as well as tumors; and one conspicuous histological feature of these diseases is the abnormal blood vessels with leaky endothelium. Hence, due to the enhanced permeability and retention effect, systemically administered drug-loaded NPs tend to accumulate in diseased tissues and are readily captured by local macrophages, leading to enhanced specificity, reduced side effects, and improved therapeutic efficacy. In a rat model of adjuvant arthritis, intravenously injected PEI-SPION/siRNA complexes were taken up by ~40% of the CD11b+ cells during the first 24 h after the injection¹⁸. In contrast, when cationic liposome was used as a carrier for systemic siRNA delivery in mice, less than 5% of the CD11b+ cells in the arthritic joints entrapped the siRNA lipoplexes²³. Moreover, owing to their magnetic properties, the application of an external magnetic field may further facilitate the accumulation of PEI-SPION/siRNA complexes in the target tissues and increase their cellular uptake. Also noteworthy is that such siRNA-loaded NPs can be used not only for modulating macrophage function but also for imaging macrophage to provide diagnostic information, monitor treatment efficacy, and predict patients' clinical outcomes¹².

However, limitations associated with this protocol do exist. The PEI-SPION system exhibits a narrow range of dosage for siRNA delivery. The maximum uptake occurred when RAW264.7 cells were exposed to PEI-SPION/siRNAs at a concentration of 15 $\mu\text{g Fe/mL}$ (**Figures 2B and 2C**). Increasing the PEI-SPION/siRNA concentration to 32 $\mu\text{g Fe/mL}$ did not result in an increase in cellular uptake (**Figure 2C**) but, on the contrary, might increase the risk of inducing cell death due to the intrinsic toxicity of PEI. On the other hand, decreasing PEI-SPION/siRNA to 5 or 7.5 $\mu\text{g Fe/mL}$ obviously reduced its uptake by RAW264.7 cells (**Figures 2B and 2C**). Thus, we propose that the optimal PEI-SPION/siRNA concentration for *in vitro* macrophage transfection is ~15 $\mu\text{g Fe/mL}$ (the final concentration in a well). Another limitation that needs to be taken into consideration is the possible effect of PEI-SPIONs on macrophage activity. Nanoparticles may induce the immune response²⁴, depending on their surface modification, surface charge, size, shape, and even on the methodology used to synthesize them. Mulens-Arias *et al.* recently reported that PEI-coated SPIONs trigger macrophage activation²⁵. The method of PEI-SPION synthesis presented here differs significantly from that of Mulens-Arias *et al.*, and therefore, whether PEI-SPIONs prepared based on the present protocol trigger macrophage activation awaits further investigation. However, to unambiguously address this concern, we suggest that, in addition to the PEI-SPION complexed with scramble siRNA, the vehicle itself (PEI-SPION only) can serve as another control when using the present protocol. Finally, this protocol is not suitable

for the delivery of DNA due to its relatively large size.

In summary, we presented here a method of using PEI-coated SPIONs as a vehicle for siRNA transfection in macrophages. These NPs can efficiently deliver siRNA into immortalized macrophage cell lines, as well as into primary macrophages *in vitro*, and functionally induce gene silencing without affecting cell viability at the optimal dose for transfection. Moreover, PEI-SPIONs may be used for *in vivo* siRNA delivery to macrophages, making it possible to image, as well as modulate, macrophages whose dysfunction contributes to the development and progression of many chronic inflammatory disorders and cancers.

ACKNOWLEDGMENTS:

This work was supported by the National Natural Science Foundation of China (81772308) and the National Key Research and Development Program of China (No. 2017YFA0205502).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Murray, P. J., Wynn, T. A. Protective and pathogenic functions of macrophage subsets. *Nature Reviews Immunology*. **11** (11), 723 (2011).
2. Maeß, M. B., Wittig, B., Lorkowski, S. Highly efficient transfection of human THP-1 macrophages by nucleofection. *Journal of Visualized Experiments*. (91), e51960 (2014).
3. Zhang, X., Edwards, J. P., Mosser, D. M. The Expression of Exogenous Genes in Macrophages: Obstacles and Opportunities. In *Macrophages and Dendritic Cells* 123-143, Springer (2009).
4. Zhang, M., Gao, Y., Caja, K., Zhao, B., Kim, J. A. Non-viral nanoparticle delivers small interfering RNA to macrophages *in vitro* and *in vivo*. *PLoS ONE*. **10** (3), e0118472 (2015).
5. Davignon, J.-L. *et al.* Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. *Rheumatology*. **52** (4), 590-598 (2012).
6. Brown, J. M., Recht, L., Strober, S. The promise of targeting macrophages in cancer therapy. *Clinical Cancer Research*. **23** (13), 3241-3250 (2017).
7. Karunakaran, D. *et al.* Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. *Science Advances*. **2** (7), e1600224 (2016).
8. Prosperi, D., Colombo, M., Zanoni, I., Granucci, F. Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases. *Seminars in Immunology*. **34**, 61-67 (2017).

9. Höbel, S., Aigner, A. Polyethylenimines for siRNA and miRNA delivery *in vivo*. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*. **5** (5), 484-501 (2013).
10. Whitehead, K. A., Langer, R., Anderson, D. G. Knocking down barriers: advances in siRNA delivery. *Nature Reviews Drug Discovery*. **8** (2), 129 (2009).
11. Liu, G. *et al.* N-Alkyl-PEI-functionalized iron oxide nanoclusters for efficient siRNA delivery. *Small*. **7** (19), 2742-2749 (2011).
12. Weissleder, R., Nahrendorf, M., Pittet, M. J. Imaging macrophages with nanoparticles. *Nature Materials*. **13** (2), 125 (2014).
13. Magro, M. *et al.* Covalently bound DNA on naked iron oxide nanoparticles: Intelligent colloidal nano-vector for cell transfection. *Biochimica et Biophysica Acta (BBA)-General Subjects*. **1861** (11), 2802-2810 (2017).
14. Abdelrahman, M. *et al.* siRNA delivery system based on magnetic nanovectors: Characterization and stability evaluation. *European Journal of Pharmaceutical Sciences*. **106**, 287-293 (2017).
15. Zhang, H., Lee, M.-Y., Hogg, M. G., Dordick, J. S., Sharfstein, S. T. Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles. *ACS Nano*. **4** (8), 4733-4743 (2010).
16. Moghimi, S. M., Hunter, A. C., Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. *Pharmacological Reviews*. **53** (2), 283-318 (2001).
17. Harvey Jr., A. E., Smart, J. A., Amis, E. Simultaneous spectrophotometric determination of iron (II) and total iron with 1, 10-phenanthroline. *Analytical Chemistry*. **27** (1), 26-29 (1955).
18. Duan, J. *et al.* Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis. *Nanomedicine*. **9** (6), 789-801 (2014).
19. Fröhlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. *International Journal of Nanomedicine*. **7**, 5577 (2012).
20. Wu, Y. *et al.* Ultra-small particles of iron oxide as peroxidase for immunohistochemical detection. *Nanotechnology*. **22** (22), 225703 (2011).
21. Xia, T. *et al.* Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. *ACS Nano*. **3** (10), 3273-3286


(2009).


22. Mocellin, S., Provenzano, M. RNA interference: learning gene knock-down from cell physiology. *Journal of Translational Medicine*. **2** (1), 39 (2004).

23. Courties, G. *et al.* *In vivo* RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. *Blood*. **116** (18), 3505-3516 (2010).


24. Zolnik, B. S., Gonzalez-Fernandez, A., Sadrieh, N., Dobrovolskaia, M. A. Minireview: nanoparticles and the immune system. *Endocrinology*. **151** (2), 458-465 (2010).

25. Mulens-Arias, V., Rojas, J. M., Pérez-Yagüe, S., Morales, M. P., Barber, D. F. Polyethylenimine-coated SPIONs trigger macrophage activation through TLR-4 signaling and ROS production and modulate podosome dynamics. *Biomaterials*. **52**, 494-506 (2015).






A



B



Name of Reagent/ Equipment	Company	Catalog Number	Comments/Description
DMEM	Gibco	C11995500BT	Warm in 37°C water bath before use
Fetal bovine serum	Gibco	A31608-02	
Penicillin/streptomycin (1.5 ml)	Gibco	15140122	
Tetrazolium-based MTS assay kit	Promega	G3582	For cytotoxicity analysis
	Cell Bank of Chinese Academy of Sciences, Shanghai, China	TCM13	
RAW 264.7 cell line	Corning	3516	
Tissue culture plates (6-well)	Corning	430167	
Tissue culture dishes (10 cm)			
RNase-free tubes (1.5 ml)	AXYGEN	MCT-150-C	
Centrifuge tubes (15 ml)	Corning	430791	
Trypsin	Gibco	25200-056	
	Shanghai Experimental Animal Center of Chinese Academy of Sciences		
Wistar rats	National Institutes for Food and Drug Control, China		
Bacillus Calmette–Guérin freeze-dried powder			for inducing adjuvant arthritis in rats

siRNA	GenePhar ma (Shanghai, China)	
Cy3-siRNA	RiboBio (Guangzho u, China)	
Polyethyleneimine (10 kDa)	Aladdin Chemical Reagent Co., Ltd.	E107079
Ammonia water	Aladdin Chemical Reagent Co., Ltd.	A112077
Oleic acid	Aladdin Chemical Reagent Co., Ltd.	O108484
Dimethylsulfoxide	Aladdin Chemical Reagent Co., Ltd.	D103272
FeSO ₄ •7H ₂ O	Sinopharm Chemical Reagent Co., Ltd	10012118
FeCl ₃ •6H ₂ O	Sinopharm Chemical Reagent Co., Ltd	10011918

Dimercaptosuccinic acid ultrafiltration tube	Aladdin Chemical Reagent	
	Co., Ltd.	D107254
	Millipore	UFC910096
Tetramethylammonium hydroxide solution	Aladdin Chemical Reagent	
	Co., Ltd.	T100882
Particle size and zeta potential analyzer	Malvern, England	Nano ZS90



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: Polyethyleneimine-coated iron oxide nanoparticles as a vehicle for delivery of small interfering RNA to macrophages in vitro and in vivo

Author(s): Na Jia, Haoan Wu, Juanli Duan, Chunxue Wei, Yu Zhang, Xiaohua Mao

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:

Xiaohua Mao

Department:

Department of Biochemistry

Institution:

Southeast University Medical School

Article Title:

Polyethyleneimine-coated iron oxide nanoparticles as a vehicle for delivery of small interfering RNA to macrophages in vitro and in vivo

Signature:



Date:

June 23, 2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Response to Reviewers' comments:

Editorial comments:

Changes to be made by the Author(s):

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

Authors' response: We have checked carefully the whole manuscript to avoid language issues.

2. Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."

Authors' response: Copyright permission has been obtained and the document has been uploaded.

3. Figure 1: Please label the molecular weight of the bands.

Authors' response: Revised as requested.

4. Figure 2: Please combine all panels of one figure into a single image file or split it into several figures.

Authors' response: Fig. 2 is now a single image.

5. Figure 2A: Please change ml to mL. Please include a space between 30 and mV (i.e., 30 mV).

Authors' response: Corrected as requested.

6. Figure 2B: Please line up the panels better. Some panels are off-set in the Figure.

Authors' response: Revised as requested.

7. Figure 2C: Please include a scale bar for all images taken with a microscope to provide context to the magnification used. Define the scale in the appropriate figure Legend.

Authors' response: Scale bars have been provided.

8. Figure 2D: Please define error bars in the figure legend.

Authors' response: The error bars have been defined.

9. Figure 3: Please include a space between numbers and their units (i.e., 2 h, 8 h, 24 h).

Authors' response: Corrected.

10. Please provide an institutional email address for each author.

Authors' response: The institutional email address for each author has been provided.

11. Please convert centrifuge speeds to centrifugal force (x g) instead of revolutions per minute (rpm).

Authors' response: Corrected.

12. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. For example: Brookhaven ZetaPlus, etc.

Authors' response: Revised.

13. Please include an ethics statement before your numbered protocol steps, indicating that the protocol follows the animal care guidelines of your institution.

Authors' response: Ethics statement has been included in the revised ms.

14. Please revise the protocol text to avoid the use of any personal pronouns (e.g., "we", "you", "our" etc.).

Authors' response: Revised as requested.

15. Please add more details to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Please ensure you answer the "how" question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.

Authors' response: Revised as requested.

16. 1.1.1: What type of water is used? How to dissolve under the protection of N₂? Where is this step performed?

Authors' response: Revised as requested. No special environment is needed to perform this step.

17. 1.3.2: How to perform purification by using 100k ultrafiltration tube? Does 100k mean 100 kDa?

Authors' response: Revised.

18. 1.3.3: Please describe how this is done.

Authors' response: Revised.

19. 2.2: Please specify the source of siRNA. Is it purchased or isolated in lab?

Authors' response: The source of siRNA used in this manuscript can be found in the Table of Materials. We don't think it is necessary to specify the source of siRNA at this step because viewers should, depending on their experimental purposes, use siRNA which may differ from those used in this manuscript. Our protocol should be suitable for delivery of any siRNAs, whatever their sequences.

20. 2.4: Please break up into sub-steps.

Authors' response: Done as requested.

21. 3.3: How long does it take for the majority of the cells to detach?

Authors' response: Specified.

22. 3.9: Does step 7 refer to step 3.7?

Authors' response: We thank the editor for careful reading of our ms. This has been corrected.

23. 4.1: Please specify the age, sex, and strain of rats.

Authors' response: Done as requested.

24. 4.3: Are rats constrained before injection? Please describe how to assess biodistribution or therapeutic effect.

Authors' response: Relevant info has been provided in the revised ms.

25. What happens to rats at the end of experiment?

Authors' response: In Section 4 of the protocol text, we describe how to deliver siRNA to macrophages in vivo using rats with adjuvant arthritis as a disease model. Because the sequence of siRNA used in this section is not provided, we don't think it is suitable here to mention what happens to rats at the end of experiment. Moreover, the therapeutic effect may vary, depending on siRNA specificity, its silencing activity, the choice of an appropriate target, dose, etc. Failure in obtaining expected therapeutic benefits does not necessarily mean infeasibility of the PEI-SPION-based siRNA transfection method.

26. After you have made all the recommended changes to your protocol (listed above), please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.

Authors' response: The essential steps for the video are highlighted in red.

27. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense. Please do not highlight any steps describing anesthetization and euthanasia.

Authors' response: Done as requested.

28. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.

Authors' response: Done as requested.

29. As we are a methods journal, please revise the Discussion to explicitly cover the following in detail in 3-6 paragraphs with citations:

- a) Critical steps within the protocol
- b) Any modifications and troubleshooting of the technique
- c) Any limitations of the technique
- d) The significance with respect to existing methods
- e) Any future applications of the technique

Authors' response: We have completely rephrased the Discussion following these instructions.

Reviewer #1:

Comments:

The authors introduced many reported researches. Some errors and inappropriate statements (including English writings and experimental data) should be corrected. Specifically, the authors should address the following points:

1. The authors reported that "we presented a method for synthesizing SPIONs whose surface was modified with low-molecular-weight, branched PEI (PEI-SPION)". However, the molecular weight of PEI used in this research was not mentioned in the manuscript, although in section of preparation of PEI-SPIONs, the resultant solution was purified by 100K ultrafiltration tube, which seems like the cut-off molecular weight of free PEI was by less than 100kDa;

Authors' response: In our initial submission the molecular weight of PEI had been described in the Table of Materials. Anyway, in the revised manuscript we also indicate the molecular weight of PEI at step 1.3.1.

2. Mulens-Arias.V et al (2015) reported that Polyethylenimine-coated SPIONs activate macrophage through TLR-4 signaling and ROS production and modulate

podosome dynamics. Then, is PEI-SPION for siRNA delivery to macrophage suitable?

Authors' response: We thank the reviewer for pointing out the potential effect of PEI-SPION on macrophage activity. Nanoparticles may induce immune response, depending on their surface modification, surface charge, size, shape and even the methodology used to synthesize them. For instance, according to the paper of Mulens-Arias et al (2015), PMag 25Br-Zonyl FSA nanoparticles (a kind of PEI-SPION) synthesized at 90 °C dose-dependently increased IL-12 secretion when incubated with THP1 macrophages, while those synthesized at room temperature did not. Our method of PEI-SPION synthesis differs significantly from that of Mulens-Arias et al., and therefore whether PEI-SPIONs prepared based on our protocol could trigger macrophage activation awaits further investigation. However, since we previously demonstrated that PEI-SPION-mediated in vivo delivery of IL-2/IL-15R siRNA to macrophages was efficacious for treating experimental arthritis, a disease model in which abnormal activation of macrophages is a key pathological event, our PEI-SPIONs might have a negligible effect on macrophage activation. To address the referee's concern, in the Discussion of the revised manuscript we advocate incorporation of PEI-SPION (vehicle only) treated cells or animals as a control group.

3. For siRNA binding assay, Fe:siRNA ratio was calculated. This referee suggests the authors provide exact nitrogen:phosphate (N/P) ratio, which is the more accurate information in terms of reproducibility;

Authors' response: The PEI-SPION we used is not a commercial product. The person who would like to try this protocol has to synthesize the nanoparticle de novo. Even if vehicle:siRNA ratio is given in the form of N/P, pilot experiments for optimizing N/P ratio remain necessary. Due to its simplicity Fe:siRNA weight ratio was used to measure the amount of PEI-SPIONs needed for siRNA binding.

4. The author said that zeta potential of PEI-SPION over +37 mV can be toxic and suggested that PEI-SPION with an average zeta potential not higher than +37 mV be used for siRNA delivery. In additionally, the authors noted that the surface charge and hydrodynamic size of nanoparticles can be controlled within a desired range by adjusting the PEI content. But PEI-SPION was prepared at only WFe: WPEI =1:3 ratio. Is this the actual ratio for siRNA delivery in this manuscript? This referee suggests that the authors mention the zeta potential and the size of this ratio, with and without siRNA loading;

Authors' response: The W_{Fe} to W_{PEI} ratio of 1:3 can serve as a starting point for synthesizing PEI-SPION suitable for siRNA delivery. We found that even for a given W_{Fe} to W_{PEI} ratio the size and charge of PEI-SPIONs prepared in independent experiments may vary to some extent. The PEI-SPIONs used in this manuscript were synthesized in separate experiments and the actual W_{Fe} to W_{PEI} ratio fluctuated about 1:3, depending on the charge and size wanted. Although the physicochemical properties of PEI-SPIONs in this manuscript differ to certain extent, these particles

showed similar siRNA binding ability and transfection efficiency except that highly positively charged particles can be toxic.

At the suggestion of the referee we provided the zeta potential and size of PEI-SPIONs in the revised figure legends. We did not provide the charge and size of the particles loaded with siRNA. We recommend performing gel retardation assay to determine the ratio of PEI-SPION (Fe content) to siRNA because using this assay siRNA binding to PEI-SPIONs can be presented in a straightforward, clear manner. Measurement of charge and size of PEI-SPION/siRNA is optional, as increase in size and decrease in zeta potential upon siRNA binding do not indicate to what extent siRNA is loaded onto PEI-SPIONs.

5. In line 271-272 and 278-279, the authors said that this figure was modified from ref. 17 and the authors are awaiting permission from the publisher. But ref.17 is not related to the present protocol. This referee suggests that the authors double check the references used in the manuscript;

Authors' response: We thank the referee for pointing out the mistakes. The two mistakes have been corrected.

Reviewer #2:

Manuscript Summary:

With the main objective of using macrophages as target for autoimmune diseases, the authors describe an interesting protocol in which PEI-SPIONs are synthesized for targeted delivery of siRNA to macrophages. In general, the manuscript is clear and copes with the aim of the journal. However, there are some points to be addressed before its acceptance.

Major Concerns:

1. There is a lack of information about the physicochemistry characteristics of the nanoparticles, mainly data about size and size distribution.

Authors' response: In the Results section we rephrased the opening sentence and provided the size and charge range of PEI-SPIONs used in this manuscript.

2. Figure legends are not clear. In addition, Fig 2 and 3, need permission from the Publisher but they correspond to an old reference. Why do not construct these figures with the results obtained by the authors?

Authors' response: In the revised figure legends we indicated the size and charge of PEI-SPIONs for each experiment. Fig. 2D and Fig. 3 were modified from our previous publication because these experiments, particularly Fig. 3, are time consuming and expensive.

Minor Concerns:

References should be revised.

Authors' response: Checked and mistakes corrected.

**Future Medicine Ltd LICENSE
TERMS AND CONDITIONS**

Jul 09, 2018

This is a License Agreement between Xiaohua Mao ("You") and CCC Republication ("CCC Republication") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by CCC Republication, and the payment terms and conditions.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

License Number	4385050864765
License date	Jun 19, 2018
Licensed content publisher	CCC Republication
Licensed content title	Nanomedicine
Licensed content date	Jan 1, 2006
Type of Use	Journal/Magazine
Requestor type	Author of requested content
Format	Electronic
Portion	image/photo
Number of images/photos requested	2
The requesting person/organization is:	Xiaohua Mao/Southeast University
Title or numeric reference of the portion(s)	Figure 3C, Figure 6C&D
Title of the article or chapter the portion is from	Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis
Editor of portion(s)	N/A
Author of portion(s)	Mao, Xiaohua ; et al
Volume of serial or monograph.	9
Issue, if republishing an article from a serial	6
Page range of the portion	794,797
Publication date of portion	May 1, 2014
Rights for	Main product and any product related to main product
Duration of use	Life of current edition
Creation of copies for the disabled	no
With minor editing privileges	yes
For distribution to	Worldwide
In the following language(s)	Original language of publication
With incidental promotional	no

use

The lifetime unit quantity of new product Up to 499

Title Polyethyleneimine-coated iron oxide nanoparticles as a vehicle for delivery of small interfering RNA to macrophages in vitro and in vivo

Author Na Jia, Juanli Duan, Chunxue Wei, Yu Zhang, Xiaohua Mao

Publication JoVE Biology

Publisher JoVE

Expected publication date Dec 2018

Expected size 4

Billing Type Invoice

Billing Address Xiaohua Mao
Southeast University

Nanjing, China
Attn: Xiaohua Mao

Total (may include CCC user fee) 0.00 USD

Terms and Conditions

TERMS AND CONDITIONS

The following terms are individual to this publisher:

None

Other Terms and Conditions:

STANDARD TERMS AND CONDITIONS

1. Description of Service; Defined Terms. This Republication License enables the User to obtain licenses for republication of one or more copyrighted works as described in detail on the relevant Order Confirmation (the "Work(s)"). Copyright Clearance Center, Inc. ("CCC") grants licenses through the Service on behalf of the rightsholder identified on the Order Confirmation (the "Rightsholder"). "Republication", as used herein, generally means the inclusion of a Work, in whole or in part, in a new work or works, also as described on the Order Confirmation. "User", as used herein, means the person or entity making such republication.

2. The terms set forth in the relevant Order Confirmation, and any terms set by the Rightsholder with respect to a particular Work, govern the terms of use of Works in connection with the Service. By using the Service, the person transacting for a republication license on behalf of the User represents and warrants that he/she/it (a) has been duly authorized by the User to accept, and hereby does accept, all such terms and conditions on behalf of User, and (b) shall inform User of all such terms and conditions. In the event such person is a "freelancer" or other third party independent of User and CCC, such party shall be deemed jointly a "User" for purposes of these terms and conditions. In any event, User shall be deemed to have accepted and agreed to all such terms and conditions if User republishes the Work in any fashion.

3. Scope of License; Limitations and Obligations.

3.1 All Works and all rights therein, including copyright rights, remain the sole and exclusive property of the Rightsholder. The license created by the exchange of an Order Confirmation (and/or any invoice) and payment by User of the full amount set forth on that document includes only those rights expressly set forth in the Order Confirmation and in these terms and conditions, and conveys no other rights in the Work(s) to User. All rights not expressly granted are hereby reserved.

3.2 General Payment Terms: You may pay by credit card or through an account with us payable at the end of the month. If you and we agree that you may establish a standing account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are payable upon their delivery to you (or upon our notice to you that they are available to you for downloading). After 30 days, outstanding amounts will be subject to a service charge of 1-1/2% per month or, if less, the maximum rate allowed by applicable law. Unless otherwise specifically set forth in the Order Confirmation or in a separate written agreement signed by CCC, invoices are due and payable on "net 30" terms. While User may exercise the rights licensed immediately upon issuance of the Order Confirmation, the license is automatically revoked and is null and void, as if it had never been issued, if complete payment for the license is not received on a timely basis either from User directly or through a payment agent, such as a credit card company.

3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is "one-time" (including the editions and product family specified in the license), (ii) is non-exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions (such as, but not limited to, limitations on duration of use or circulation) included in the Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the licensed use, User shall either secure a new permission for further use of the Work(s) or immediately cease any new use of the Work(s) and shall render inaccessible (such as by deleting or by removing or severing links or other locators) any further copies of the Work (except for copies printed on paper in accordance with this license and still in User's stock at the end of such period).

3.4 In the event that the material for which a republication license is sought includes third party materials (such as photographs, illustrations, graphs, inserts and similar materials) which are identified in such material as having been used by permission, User is responsible for identifying, and seeking separate licenses (under this Service or otherwise) for, any of such third party materials; without a separate license, such third party materials may not be used.

3.5 Use of proper copyright notice for a Work is required as a condition of any license granted under the Service. Unless otherwise provided in the Order Confirmation, a proper copyright notice will read substantially as follows: "Republished with permission of [Rightsholder's name], from [Work's title, author, volume, edition number and year of copyright]; permission conveyed through Copyright Clearance Center, Inc. " Such notice must be provided in a reasonably legible font size and must be placed either immediately adjacent to the Work as used (for example, as part of a by-line or footnote but not as a separate electronic link) or in the place where substantially all other credits or notices for the new work containing the republished Work are located. Failure to include the required notice results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated damages for each such failure equal to twice the use fee specified in the Order Confirmation, in addition to the use fee itself and any other fees and charges specified.

3.6 User may only make alterations to the Work if and as expressly set forth in the Order Confirmation. No Work may be used in any way that is defamatory, violates the rights of third parties (including such third parties' rights of copyright, privacy, publicity, or other tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In addition, User may not conjoin a Work with any other material that may result in damage to the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any infringement of any rights in a Work and to cooperate with any reasonable request of CCC or the Rightsholder in connection therewith.

4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and their respective employees and directors, against all claims, liability, damages, costs and expenses, including legal fees and expenses, arising out of any use of a Work beyond the scope of the rights granted herein, or any use of a Work which has been altered in any

unauthorized way by User, including claims of defamation or infringement of rights of copyright, publicity, privacy or other tangible or intangible property.

5. **Limitation of Liability.** UNDER NO CIRCUMSTANCES WILL CCC OR THE RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK, EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their respective employees and directors) shall not exceed the total amount actually paid by User for this license. User assumes full liability for the actions and omissions of its principals, employees, agents, affiliates, successors and assigns.

6. **Limited Warranties.** THE WORK(S) AND RIGHT(S) ARE PROVIDED "AS IS". CCC HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS, GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.

7. **Effect of Breach.** Any failure by User to pay any amount when due, or any use by User of a Work beyond the scope of the license set forth in the Order Confirmation and/or these terms and conditions, shall be a material breach of the license created by the Order Confirmation and these terms and conditions. Any breach not cured within 30 days of written notice thereof shall result in immediate termination of such license without further notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon notice thereof may be liquidated by payment of the Rightsholder's ordinary license price therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any reason (including, for example, because materials containing the Work cannot reasonably be recalled) will be subject to all remedies available at law or in equity, but in no event to a payment of less than three times the Rightsholder's ordinary license price for the most closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses incurred in collecting such payment.

8. Miscellaneous.

8.1 User acknowledges that CCC may, from time to time, make changes or additions to the Service or to these terms and conditions, and CCC reserves the right to send notice to the User by electronic mail or otherwise for the purposes of notifying User of such changes or additions; provided that any such changes or additions shall not apply to permissions already secured and paid for.

8.2 Use of User-related information collected through the Service is governed by CCC's privacy policy, available online here:

<http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html>.

8.3 The licensing transaction described in the Order Confirmation is personal to User. Therefore, User may not assign or transfer to any other person (whether a natural person or an organization of any kind) the license created by the Order Confirmation and these terms and conditions or any rights granted hereunder; provided, however, that User may assign such license in its entirety on written notice to CCC in the event of a transfer of all or substantially all of User's rights in the new material which includes the Work(s) licensed under this Service.

8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed by the parties. The Rightsholder and CCC hereby object to any terms contained in any

writing prepared by the User or its principals, employees, agents or affiliates and purporting to govern or otherwise relate to the licensing transaction described in the Order Confirmation, which terms are in any way inconsistent with any terms set forth in the Order Confirmation and/or in these terms and conditions or CCC's standard operating procedures, whether such writing is prepared prior to, simultaneously with or subsequent to the Order Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a separate instrument.

8.5 The licensing transaction described in the Order Confirmation document shall be governed by and construed under the law of the State of New York, USA, without regard to the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding arising out of, in connection with, or related to such licensing transaction shall be brought, at CCC's sole discretion, in any federal or state court located in the County of New York, State of New York, USA, or in any federal or state court whose geographical jurisdiction covers the location of the Rightsholder set forth in the Order Confirmation. The parties expressly submit to the personal jurisdiction and venue of each such federal or state court. If you have any comments or questions about the Service or Copyright Clearance Center, please contact us at 978-750-8400 or send an e-mail to info@copyright.com.

v 1.1

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.
